Abstract | BACKGROUND:
Rhinitis affects a significant proportion of adults and children with typically seasonal or chronic symptoms. Botulinum neurotoxin type A (BoNTA) is a well-known cholinergic antagonist widely used in a number of approved neurological and esthetic indications. This study was designed to assess the therapeutic effect of RT001, a novel topical gel formulation of BoNTA, in the treatment of allergic rhinitis using a rat model and to compare its safety profile with that of an aqueous formulation of BoNTA complex. METHODS: RESULTS: CONCLUSION: These results suggest that topical intranasal application of RT001 is effective in relief of clinical signs and inflammatory pathology associated with allergic rhinitis in a rodent model and may provide a safe treatment for rhinitis.
|
Authors | Zhao Zhu, Hongran F Stone, Thai Q D Thach, Luke Garcia, Curtis L Ruegg |
Journal | American journal of rhinology & allergy
(Am J Rhinol Allergy)
2012 Nov-Dec
Vol. 26
Issue 6
Pg. 450-4
ISSN: 1945-8932 [Electronic] United States |
PMID | 23232194
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gels
- Botulinum Toxins, Type A
|
Topics |
- Administration, Topical
- Animals
- Botulinum Toxins, Type A
(administration & dosage, adverse effects)
- Female
- Gels
- Guinea Pigs
- Immunohistochemistry
- Rats
- Rats, Sprague-Dawley
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
(drug therapy, metabolism, pathology)
|